Moderate-to-severe asthma represents 15–30% of asthma patients but accounts for more than half of healthcare costs and a disproportionate share of morbidity. Despite this clinical burden, the genetic mechanisms distinguishing mild asthma from moderate-to-severe asthma are incompletely defined. The authors conducted separate pooled multi-ancestry genome-wide association studies to compare genetic susceptibility between these two clinical severity strata and to identify both shared and phenotype-specific loci and pathways.
Analyses used adult participant data from the NIH All of Us Research Program (version 8). Cases were grouped as mild asthma (N = 14,372) or moderate-to-severe asthma (N = 7,096), each compared to the same non-asthma control set (N = 28,816). The report describes separate pooled GWAS for each asthma phenotype.
Ancestry-specific GWAS were run for European, African, and Latino/admixed groups and then combined using fixed-effect meta-analysis. This multi-ancestry approach aimed to capture both shared signals across populations and ancestry-informative associations.
To prioritize candidate genes and biological mechanisms, the study integrated lung expression quantitative trait loci (eQTL) data and performed pathway enrichment analyses. These analyses were applied across the asthma phenotypes to map loci to likely effector genes and to identify enriched immune and cellular pathways associated with each severity group.
The GWAS identified multiple loci shared between mild and moderate-to-severe asthma. Shared susceptibility regions included IL1RL1, IKZF3, and the genomic regions spanning GTF3AP1-IL33, GTF3AP1-RANBP6, LINC02757-EMSY, and HLA-DRB1-HLA-DQA1. Integration with lung eQTLs implicated candidate genes such as IL18R1, IL18RAP, HLA genes, IL33, LRRC32, GRB7, MIEN1, and GSDMB as contributors to shared susceptibility.
Mild asthma displayed broader signals across HLA class II regions and showed associations at SMAD3 and GSDMB. Pathway enrichment for the mild phenotype highlighted processes related to antigen presentation, T-helper cell differentiation, and TGF-β regulation. The authors interpret these signals as consistent with dominant contributions from adaptive immune mechanisms in mild disease.
Moderate-to-severe asthma exhibited distinct association peaks at WDR36 and PTCH1. Lung eQTL analyses for this phenotype implicated TSLP, CAMK4, and FANCC as potential effector genes. Pathway analysis for moderate-to-severe disease identified enrichment for pathways including IL-13, IL-6, and IL-10 production, myeloid leukocyte differentiation, and oxidative stress responses—findings the authors link to innate inflammatory mechanisms and pathways previously associated with steroid resistance.
The region around IL33 showed a severity-gradient effect, with stronger association signals in moderate-to-severe asthma compared with mild asthma. This gradient supports a role for IL33-related biology in more severe disease, according to the study's results.
Overall, the findings indicate that while mild and moderate-to-severe asthma share multiple susceptibility loci, they also have distinct genetic architectures pointing to different dominant immune and cellular mechanisms. Mild asthma signals are consistent with adaptive immune function and antigen presentation, whereas moderate-to-severe asthma signals implicate innate immunity, myeloid differentiation, oxidative stress responses, and pathways linked to steroid resistance. The authors note that these results support existing biologic targets and suggest additional candidate genes and pathways that could inform therapeutic development.
The study used publicly available data accessible through the NIH All of Us Research Program workbench. The authors state that relevant ethical guidelines were followed and that appropriate IRB/oversight approvals and participant consents were obtained through the All of Us program. Declared funders include the National Institute of Allergy and Infectious Diseases (R21AI193971) and the National Institute of Environmental Health Sciences (Z01 ES102005, Z01 ES025041).
This report is a medRxiv preprint posted September 22, 2026, and has not undergone peer review. The authors explicitly declare no competing interests. As with any preprint, the findings should not be used to guide clinical practice until validated and peer reviewed. The manuscript provides links to supplementary material, data/code, and the full PDF for further detail.